ALCAM and non-small cell lung carcinoma: However, more than 84% of α2δ1+ cells were clearly CD166 positive but not vice versa in these cell lines (Fig. 3E), suggesting that α2δ1+ cells are a subset of CD166+ NSCLC cells.